Tufia C Haddad Selected Research

Tufia C Haddad Research Topics

Disease

27	Breast Neoplasms (Breast Cancer) 05/2024 - 12/2014
19	Neoplasms (Cancer) 01/2024 - 01/2006
5	Triple Negative Breast Neoplasms 04/2022 - 07/2016
4	Heart Failure 01/2023 - 12/2014
3	Neutropenia 11/2023 - 10/2022
2	Ductal Carcinoma 07/2023 - 03/2023
2	Lymphoma (Lymphomas) 01/2023 - 01/2020
2	Fatigue 10/2022 - 01/2019
2	Residual Neoplasm 01/2022 - 07/2016
2	Disease Progression 01/2020 - 04/2018
2	Cardiotoxicity 09/2017 - 12/2014
1	Inflammatory Breast Neoplasms 01/2024
1	Overweight 11/2023
1	Anemia 01/2023
1	Mouth Neoplasms (Oral Cancer) 10/2022
1	Ataxia Telangiectasia (Louis Bar Syndrome) 04/2022
1	Unilateral Breast Neoplasms 01/2022
1	COVID-19 01/2021
1	Neoplasm Metastasis (Metastasis) 01/2021
1	Alopecia (Baldness) 12/2020
1	Lymphedema (Milroy Disease) 01/2019
1	Peripheral Nervous System Diseases (PNS Diseases) 01/2019
1	Cognitive Dysfunction 01/2019
1	Chronic Disease (Chronic Diseases) 01/2018
1	Noninfiltrating Intraductal Carcinoma (DCIS) 02/2016
1	Hyperplasia 02/2016
1	Hypertension (High Blood Pressure) 12/2014
1	Thrombosis (Thrombus) 01/2006

Drug/Important Bio-Agent (IBA)

7	Hormones (Hormone)IBA 11/2023 - 07/2016
5	Trastuzumab (Herceptin)FDA Link 07/2021 - 12/2014
4	Biomarkers (Surrogate Marker)IBA 01/2022 - 05/2015
3	palbociclibIBA 11/2023 - 01/2022
3	Fulvestrant (Faslodex)FDA Link 01/2023 - 04/2018
3	Aurora Kinase AIBA 01/2023 - 04/2018
3	ErbB Receptors (EGF Receptor)IBA 10/2022 - 12/2014
3	Estrogen ReceptorsIBA 01/2020 - 02/2016
3	human ERBB2 proteinIBA 09/2017 - 02/2016
2	Anastrozole (Arimidex)FDA LinkGeneric 05/2024 - 01/2021
2	Estrogens (Estrogen)FDA Link 05/2024 - 01/2021
2	Paclitaxel (Taxol)FDA LinkGeneric 01/2024 - 08/2017
2	AnthracyclinesIBA 01/2023 - 01/2020
2	MLN 8237IBA 01/2023 - 04/2018
2	Cyclin-Dependent Kinase 4IBA 11/2022 - 01/2022
2	Lapatinib (GW572016)FDA Link 07/2021 - 07/2015
2	Docetaxel (Taxotere)FDA Link 01/2021 - 08/2017
1	Estrone FDA Link 05/2024
1	Estradiol (Delestrogen)FDA LinkGeneric 05/2024
1	RNA (Ribonucleic Acid)IBA 01/2024
1	ruxolitinibIBA 01/2024
1	berzosertibIBA 04/2022
1	Cisplatin (Platino)FDA LinkGeneric 04/2022
1	PlatinumIBA 04/2022
1	Phenobarbital (Luminal)FDA Link 01/2022
1	Capecitabine (Xeloda)FDA Link 07/2021
1	cixutumumabIBA 07/2021
1	sapanisertibIBA 01/2021
1	Everolimus FDA Link 01/2021
1	Phosphotransferases (Kinase)IBA 01/2021
1	exemestane (Aromasin)FDA Link 01/2021
1	enzalutamideIBA 01/2020
1	Androgen Receptors (Androgen Receptor)IBA 01/2020
1	Brain Natriuretic Peptide (Natrecor)FDA Link 01/2020
1	Proteins (Proteins, Gene)FDA Link 01/2020
1	2- (3- (2- (1- isopropyl- 3- methyl- 1H- 1,2- 4- triazol- 5- yl)- 5,6- dihydrobenzo(f)imidazo(1,2- d)(1,4)oxazepin- 9- yl)- 1H- pyrazol- 1- yl)- 2- methylpropanamideIBA 01/2020
1	Doxorubicin (Adriamycin)FDA LinkGeneric 08/2017
1	Cyclophosphamide (Cytoxan)FDA LinkGeneric 08/2017
1	neratinibIBA 07/2016
1	Carboplatin (JM8)FDA LinkGeneric 07/2016
1	veliparibIBA 07/2016
1	Drug CombinationsIBA 07/2015
1	Tyrosine Kinase InhibitorsIBA 07/2015

Therapy/Procedure

16	Therapeutics 01/2024 - 12/2014
11	Drug Therapy (Chemotherapy) 11/2023 - 01/2006
4	Neoadjuvant Therapy 01/2022 - 05/2015
3	Mastectomy (Mammectomy) 07/2023 - 01/2018
2	Segmental Mastectomy (Lumpectomy) 07/2023 - 03/2023
2	Aftercare (After-Treatment) 01/2020 - 01/2020
2	Adjuvant Chemotherapy 01/2018 - 08/2017
1	Immunotherapy 01/2024
1	Integrative Oncology 01/2023
1	Complementary Therapies (Alternative Medicine) 12/2020
1	Radiotherapy 03/2018